Address: Schlossstrasse 14, 79232 March-Buchheim, Germany
Tel: +49 761 203 5127
Fax: +49 761 203 5191


LOGOPHARM GmbH is a research based biotech organisation which specialises in proteomic targets and biomarker R&D solutions. LOGOPHARM was founded in 2005 by a team of highly skilled lead scientists and business minded professionals in Freiburg, Germany. The organisation combines expertise in proprietary proteomic technologies, functional membrane protein analysis and molecular physiology. Based on our level of experience and expertise we conduct independent research and offer tools, specialised services including research consulting and implementation of technology tailored to our customer’s requirements.

As a client of LOGOPHARM’s you would benefit from the following competitive advantages:

The executive team is made up of scientific experts in the fields of membrane protein biochemistry, molecular physiology and mass spectrometry. Our unique and personalised approach is based on using native source material (close to physiology) and is applicable to all types of protein research especially membrane proteins, protein complexes and low-abundance proteins.

LOGOPHARM develops and uses proprietary technology and knowledge in the following areas:

  • Membrane protein solubilisation and fractionation
  • Affinity purification and protein-protein-interactions
  • Micro-proteomic analysis
  • Mass spectrometry (including quantification)
  • Bioinformatics

LOGOPHARM’s internal database currently compromises of more than 2000 membrane protein target purifications which represent a unique source of unpublished information which allows us to be fast and highly effective in our service. Due to our unique in-house expertise, infrastructure and relationship with academic research institutions, we are able to offer a cost effective solution using the latest technology.


To learn more about LOGOPHARM's services and capabilities and how they can assist your business, please contact LOGOPHARM directly.

Follow us on:
Supplier's News Feed
  • Drug Discovery